Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232
- Conditions
- Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +10 more
- Locations
-
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center Los Angeles, California, United States
- University of California, Los Angeles Los Angeles, California, United States
- Stanford Cancer Institute Palo Alto, California, United States
- University of California, San Francisco San Francisco, California, United States